ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 40 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $40,000 | -87.3% | 26,579 | -65.9% | 0.00% | – |
| Q2 2019 | $314,000 | -75.2% | 77,990 | -73.5% | 0.00% | -100.0% |
| Q1 2019 | $1,267,000 | +2.9% | 294,573 | +37.5% | 0.00% | 0.0% |
| Q4 2018 | $1,231,000 | +249.7% | 214,161 | +582.8% | 0.00% | – |
| Q1 2018 | $352,000 | -35.4% | 31,367 | -61.6% | 0.00% | -100.0% |
| Q4 2017 | $545,000 | -18.5% | 81,620 | -0.1% | 0.00% | 0.0% |
| Q3 2017 | $669,000 | +320.8% | 81,739 | +130.3% | 0.00% | – |
| Q2 2017 | $159,000 | -68.6% | 35,496 | -61.4% | 0.00% | -100.0% |
| Q1 2017 | $506,000 | +24.3% | 91,867 | -8.6% | 0.00% | 0.0% |
| Q4 2016 | $407,000 | -29.8% | 100,523 | +22.1% | 0.00% | 0.0% |
| Q3 2016 | $580,000 | +537.4% | 82,307 | +639.5% | 0.00% | – |
| Q2 2016 | $91,000 | -5.2% | 11,130 | -5.9% | 0.00% | – |
| Q1 2016 | $96,000 | -65.6% | 11,832 | -22.3% | 0.00% | – |
| Q2 2015 | $279,000 | – | 15,232 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |